With 1.54 million shares changed hands, the volume of the stock remained heavier than its average volume of 50870.0 shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $2.49 whereas the lowest price it dropped to was $2.1. The 52-week range on AMIX shows that it touched its highest point at $70.10 and its lowest point at $1.52 during that stretch. It currently has a 1-year price target of $11.50. Beta for the stock currently stands at -3.74.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AMIX was up-trending over the past week, with a rise of 15.27%, but this was up by 33.71% over a month. Three-month performance dropped to -24.27% while six-month performance fell -69.65%. The stock lost -96.52% in the past year, while it has lost -37.77% so far this year. A look at the trailing 12-month EPS for AMIX yields -12.53 with Next year EPS estimates of -4.29. For the next quarter, that number is -1.24. This implies an EPS growth rate of 60.65% for this year and -8.47% for next year.
Float and Shares Shorts:
At present, 2.46 million AMIX shares are outstanding with a float of 1.94 million shares on hand for trading. On 2025-04-15, short shares totaled 81747.0, which was 332.0 higher than short shares on 1741910400. In addition to Dr. Robert Schwartz M.D. as the firm’s Co-Founder & Chief Medical Officer, Mr. Landy Toth serves as its Co-Founder & Chief Technology Officer.
Institutional Ownership:
Through their ownership of 0.19885 of AMIX’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, AMIX reported revenue of $0.0 and operating income of -$2747000.0. The EBITDA in the recently reported quarter was -$2620000.0 and diluted EPS was -$1.46.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With AMIX analysts setting a high price target of 18.0 and a low target of 5.0, the average target price over the next 12 months is 11.5. Based on these targets, AMIX could surge 669.23% to reach the target high and rise by 113.68% to reach the target low. Reaching the average price target will result in a growth of 391.45% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
